Evidence map›Paper›PMID 37112288›Full record

ArticleSensors (Basel, Switzerland)2023

Enhancing Evanescent Wave Coupling of Near-Surface Waveguides with Plasmonic Nanoparticles.

Jerome Lapointe, Alexandre Grégoire, Jean-Philippe Bérubé, Réal Vallée

Abstract read
In one paragraph

Article in Sensors (Basel, Switzerland), 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Jerome LapointeCentre d'Optique, Photonique et Laser, Université Laval, 2375 Rue de la Terrasse, Québec, QC G1V 0A6, Canada.ORCID 0000-0002-3155-1871
Alexandre GrégoireCentre d'Optique, Photonique et Laser, Université Laval, 2375 Rue de la Terrasse, Québec, QC G1V 0A6, Canada.
Jean-Philippe BérubéCiena Corporation, 505 Boulevard du Parc Technologique, Suite 100, Québec, QC G1P 4S9, Canada.
Réal ValléeCentre d'Optique, Photonique et Laser, Université Laval, 2375 Rue de la Terrasse, Québec, QC G1V 0A6, Canada.

Funding

Canada First Research Excellence Fund Sentinel North
6 · The paper itself

Abstract

Evanescent field excitation is a powerful means to achieve a high surface-to-bulk signal ratio for bioimaging and sensing applications. However, standard evanescent wave techniques such as TIRF and SNOM require complex microscopy setups. Additionally, the precise positioning of the source relative to the analytes of interest is required, as the evanescent wave is critically distance-dependent. In this work, we present a detailed investigation of evanescent field excitation of near-surface waveguides written using femtosecond laser in glass. We studied the waveguide-to-surface distance and refractive index change to attain a high coupling efficiency between evanescent waves and organic fluorophores. First, our study demonstrated a reduction in sensing efficiency for waveguides written at their minimum distance to the surface without ablation as the refractive index contrast of the waveguide increased. While this result was anticipated, it had not been previously demonstrated in the literature. Moreover, we found that fluorescence excitation by waveguides can be enhanced using plasmonic silver nanoparticles. The nanoparticles were also organized in linear assemblies, perpendicular to the waveguide, with a wrinkled PDMS stamp technique, which resulted in an excitation enhancement of over 20 times compared to the setup without nanoparticles.

Indexed as

evanescent wave sensorfemtosecond laser writingPDMS stamp techniqueplasmonic nanoparticlessurface waveguide

Identifiers

PMID37112288
PMCPMC10144640

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.